Рrognostic value of proadrenomedullin in patients with COVID-19

Introduction. In the context of a pandemic, it is necessary to quickly and accurately stratify patients into groups based on  the severity of their condition and prognostic risk. For these purposes, some available biomarkers, such as proadrenomedullin, can be used. Objective. To determine the prognostic value of regional mean proadrenomedullin (pro-ADM) in comparison with routine clinical and laboratory parameters in patients with a new coronavirus infection COVID-19. Materials and methods. The study included 140 patients who were hospitalized with a diagnosis of community-acquired pneumonia on the background of COVID-19. The level of pro-ADM was determined on the first and third days of hospitalization by ELISA. In accordance with the outcome of the disease, patients were divided into two groups: those discharged with recovery or improvement (n = 110, 78, 6%) and those who died during their stay in the hospital (n = 30, 21, 4%). Results. Pro-ADM had the highest prognostic value as a predictor of adverse outcome on day 1 AUC ROC 0.72 95% CI (0.57–0.84) sensitivity 79.2%, specificity 62.9% and on day 3 AUC ROC 0.98 95% CI (0.86–1.0) sensitivity 100%, specificity 95.6%. ROC analysis results for C-reactive protein AUC ROC 0.55 95% CI (0.41–0.77), sensitivity 73.3%, specificity 45.6%; procalcitonin AUC ROC 0.62 95% CI (0.49–0.73), sensitivity 80%, specificity 48.2%. The relative risk of a poor outcome for a proADM level > 500 pmol/L is 2.3 95% CI (1.23–4.32), and for a proADM level > 700 it is 8.5 95% CI (4.83–14.94) p < 0.001. Conclusions. Compared to C-reactive protein and procalcitonin, regional mean proadrenomedullin has the highest predictive value as a predictor of death in patients with COVID-19.

1. Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489–493. https://doi.org/10.1126/science.abb3221.

2. Gupta A., Madhavan M., Sehgal K., Nair N., Mahajan S., Sehrawat T. et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017– 1032. https://doi.org/10.1038/s41591-020-0968-3.

3. Qiu P., Zhou Y., Wang F., Wang H., Zhang M., Pan X. et al. Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. Aging Clin Exp Res. 2020;32(9):1869–1878. https://doi.org/10.1007/s40520-020-01664-3.

4. Shi C., Wang L., Ye J., Gu Z., Wang S., Xia J. et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and metaanalysis. BMC Infect Dis. 2021;21(1):663. https://doi.org/10.1186/s12879-021-06369-0.

5. Wilson D., Schefold J., Baldirà J., Spinetti T., Saeed K., Elke G. Adrenomedullin in COVID-19 induced endotheliitis. Crit Care. 2020;24(1):411. https://doi.org/10.1186/s13054-020-03151-7.

6. Schönauer R., Els-Heindl S., Beck-Sickinger A. Adrenomedullin – new perspectives of a potent peptide hormone. J Pept Sci. 2017;23(7–8):472– 485. https://doi.org/10.1002/psc.2953.

7. Cheung В.M., Tang F. Adrenomedullin: Exciting New Horizons. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(1):4–17. https://doi.org/10.2174/187221412799015263.

8. Kato J., Kobayashi K., Etoh T., Tanaka M., Kitamura K., Imamura T. et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996;81(1):180–183. https://doi.org/10.1210/jcem.81.1.8550749.

9. Spoto S., Fogolari M., De Florio L., Minieri M., Vicino G., Legramante J. et al. Procalcitonin and MR-proAdrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock. Microb Pathog. 2019;137:103763. https://doi.org/10.1016/j.micpath.2019.103763.

10. Morgenthaler N., Struck J., Alonso C., Bergmann A. Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay. Clin Chem. 2005;51(10):1823–1829. https://doi.org/10.1373/clinchem.2005.051110.

11. Legramante J., Mastropasqua M., Susi B., Porzio O., Mazza M., Miranda Agrippino G. et al. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB. PLоS ONE. 2017;12(11):e0187702. https://doi.org/10.1371/journal.pone.0187702.

12. Stalenhoef J., van Nieuwkoop C., Wilson D., van der Starre W., Delfos N., Leyten E. et al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection. J Infect. 2018;77(1):18–24. https://doi.org/10.1016/j.jinf.2018.05.007.

13. Bivona G., Agnello L., Ciaccio M. Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021;41(6):540–548. https://doi.org/10.3343/alm.2021.41.6.540.

14. Hupf J., Mustroph J., Hanses F., Evert K., Maier L., Jungbauer C. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit Care. 2020;24(1):527. https://doi.org/10.1186/s13054-020-03246-1.

15. Gu S., Tyagi T., Jain K., Gu V., Lee S., Hwa J. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2020;18(3):194–209. https://doi.org/10.1038/s41569-020-00469-1.

16. Spoto S., Agrò F., Sambuco F., Travaglino F., Valeriani E., Fogolari M. et al. High value of mid‐regional proadrenomedullin in COVID‐19: A marker of widespread endothelial damage, disease severity, and mortality. J Med Virol. 2021;93(5):2820–2827. https://doi.org/10.1002/jmv.26676.

17. Christ-Crain M., Morgenthaler N., Stolz D., Müller C., Bingisser R., Harbarth S. et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10(3):R96. https://doi.org/10.1186/cc4955.

18. Mebazaa A., Geven C., Hollinger A., Wittebole X., Chousterman B., Blet A. et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018;22(1):354. https://doi.org/10.1186/s13054-018-2243-2.

19. Montrucchio G., Sales G., Rumbolo F., Palmesino F., Fanelli V., Urbino R. et al. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study. PLоS ONE. 2021;16(2):e0246771. https://doi.org/10.1371/journal.pone.0246771.

20. Angeletti S., Spoto S., Fogolari M., Cortigiani M., Fioravanti M., De Florio L. et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-proAdrenomedullin (MR-proADM) in bacterial infections. APMIS. 2015;123(9):740–748. https://doi.org/10.1111/apm.12406.